Azacitidine + Nivolumab for Brain Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, you must be on a stable or decreasing dose of corticosteroids for at least 7 days before enrollment.
What data supports the effectiveness of the drug combination Azacitidine and Nivolumab for brain cancer?
Research shows that Nivolumab, part of the drug combination, has shown some effectiveness in treating brain metastases (cancer spread to the brain) in patients with non-small cell lung cancer, with some patients experiencing a reduction in brain tumors. This suggests potential for Nivolumab's effectiveness in brain cancer treatment.12345
Is the combination of Azacitidine and Nivolumab safe for humans?
Nivolumab, used in combination with other drugs, has shown some safety concerns, including immune-related side effects like fatigue, nausea, and more serious neurological effects such as encephalitis (brain inflammation). However, these effects are often reversible with appropriate treatment, and the drug has been used safely in various cancer treatments.13678
How is the drug combination of Azacitidine and Nivolumab unique for brain cancer treatment?
The combination of Azacitidine and Nivolumab for brain cancer is unique because Nivolumab is an immune checkpoint inhibitor that helps the immune system attack cancer cells, and it has shown potential intracranial activity in other cancers like melanoma and lung cancer. This approach is novel as it leverages the immune system to target brain cancer, which is challenging due to the blood-brain barrier that typically limits drug delivery.1591011
What is the purpose of this trial?
This is a single-arm open-label phase 1 dose escalation/expansion trial assessing the safety and efficacy of concurrent intrathecal azacitidine and intrathecal nivolumab in recurrent high-grade glioma.
Eligibility Criteria
This trial is for patients with recurrent high-grade glioma, a type of brain cancer. Participants must have specific forms of this condition, such as Glioblastoma or Diffuse Midline Glioma. Detailed inclusion and exclusion criteria are not provided but would typically involve health status and prior treatments.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive intrathecal azacitidine and nivolumab with dose escalation and monitoring for safety and efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Azacitidine
- Intrathecal Administration
- Nivolumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Andrew P. Groves
Lead Sponsor